Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 186, Issue 4, Pages 561-564Publisher
WILEY
DOI: 10.1111/bjh.15968
Keywords
essential thrombocythaemia; interferon; thrombosis; therapy; cytoreduction; myeloproliferative disorder
Categories
Ask authors/readers for more resources
Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFN alpha)-2a/2b and pegylated (PEG)-IFN-alpha-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFN alpha or (PEG)-IFN-alpha-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available